Information and calculation tools by Rachid Asen. Not investment advice or research.

Disclaimer. Information tool. Compiles data published by NSE and BSE and calculations from the exchanges' published ESM and ASM criteria. Prices are end-of-day, not live: updated each evening after trading ends. Ethical business criteria are matched by AI, which can make mistakes; this is a criteria match, not a certification, fatwa, rating or advice. Check the company's filings. Not investment advice, research or a recommendation to buy, sell or hold any security; not SEBI-registered as an Investment Adviser or Research Analyst. Calculated dates are the earliest a security could become eligible; inclusion, stage changes and exit are decided solely by the exchanges. ESM, ASM and GSM shortlisting are surveillance measures and not an adverse action against the company. Data may be delayed or inaccurate; verify with the exchange.

NOVELIX PHARMACEUTICALS LIMITE

NOVELIX (BSE 536565) · ISIN INE314I01036 · Healthcare Research, Analytics & Technology · Est. 1994 · listed 2013 · website

Not on any surveillance list

Quarterly results

No quarterly results stored for this company yet.

Balance sheet

Balance sheet, ₹ crore (as filed)
As of	Total equity	Borrowings	Total assets
31 Mar 2026 standalone	₹46.49 cr	₹4.32 cr	₹92.42 cr
30 Sep 2025 standalone	₹25.61 cr	₹0 cr	₹71.8 cr
31 Mar 2025 standalone	₹17.54 cr	₹0 cr	₹27.21 cr

Shareholding

Shareholding pattern, Sep 2026
Promoter	FII	DII	Public
54.29%	—	—	45.71%

Latest filings

Attached 1 October 2026 · BSE
Submission of Voting results & Scrutinizers Report. 1 October 2026 · BSE
Submission of Outcome of the 32nd Annual General Meeting. 30 September 2026 · BSE
Attached. 7 September 2026 · BSE
Annual Report FY2025-26 (New) 7 September 2026 · BSE

Other companies in Healthcare Research, Analytics & Technology

Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 29 October 2026.

Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.